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Agonistotrigine (LTG) is found to activate adult muscle nicotinic acetylcholine receptors
(AChR). Single-channel patch-clamp recordings showed that LTG (0.05–400 μM) applied alone is able to open
AChR channels. [125I]α-bungarotoxin-binding studies further indicate that LTG does not bind to the canonical
ACh-binding sites. Fluorescence experiments using the probe crystal violet demonstrate that LTG induces the
transition from the resting state to the desensitized state of the AChR in the presence of excess α-
bungarotoxin, that is, when the agonist site is blocked. Allosterically-potentiating ligands or the open-
channel blocker QX-314 exhibited a behavior different from that of LTG. We conclude that LTG activates the
AChR through a site that is different from those of full agonists/competitive antagonists and allosterically-
potentiating ligands, respectively.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionNicotinic acetylcholine receptors (AChRs) are pentameric oligo-
mers present in neuronal and non-neuronal cells [1–3]. There has
been growing interest in the study of receptor ligands owing to the
involvement of AChRs in a variety of central nervous system disorders
such as epilepsy, Alzheimer's disease and Parkinson's disease [4–7].
In recent years a number of unconventional ligands that modulate
AChR activity have been discovered. Galantamine and physostigmine
are representative compounds within this class, termed allosterically-
potentiating ligands (APL) [8]. Both drugs are plant-derived inhibitors
of acetylcholinesterase and have been used for symptomatic treat-
ment of Alzheimer's disease [9]. These drugs can activate and
potentiate AChR function [9–12]. Evidence suggests that APL-like
molecules open the AChR channel by binding to a site different from
that of canonical nicotinic agonists. Furthermore, photoafﬁnity
labeling studies using [3H]physostigmine demonstrated labeling of
Lys125 in the Torpedo AChRα subunit, suggesting that this residue may
participate in the APL–AChR interaction [13] even though this amino
acid is not part of the nicotinic agonist binding site.
Lamotrigine (LTG) is an anticonvulsive drug used in the treatment
of partial epilepsies. The major pharmacological effect of LTG reported
to date is the blockage of voltage-dependent sodium channel
conductance [14–17]. Recent studies from our laboratory showed
that in the presence of ACh, LTG behaves as a typical muscle AChR
open-channel blocker [18]. Here LTG is shown to be an activator of the4 291 4861200.
om (F.J. Barrantes).
l rights reserved.adult-typemuscle AChR channel, acting through a site that is different
from that of nicotinic agonists, competitive antagonists and APL-type
molecules.
2. Materials and methods
2.1. Chemicals
Lamotrigine (6-(2,3-dichlorophenyl) 1,2,4-triazine-3, 5-diamine)
was purchased from GlaxoSmithKline (Co. Durham, UK). Carbamoyl-
choline chloride (Carb) and acetylcholine chloride (ACh) were
purchased from Sigma and stored at −20 °C in a 10 mM aqueous
stock solution. Crystal Violet (CrV) was purchased from Sigma-Aldrich
(St. Louis, MO). Alpha-bungarotoxin (αBTX) was purchased from
Sigma; [125I] was purchased from New England Nuclear (Boston, MA)
and [125I]αBTX was prepared in our laboratory by radioiodination of
coldαBTX using the chloramine-T method [19]. The speciﬁc activity of
[125I]αBTX was estimated to be 25 μCi/nmol.
2.2. Cell culture
CHO-K1/A5 is a cell line developed in our laboratory [20] that
expresses adult muscle-type AChR. Cells were cultured in Ham's-F12
medium supplemented with 10% bovine fetal serum and 40 mg/ml of
the selection antibiotic G418 (Sigma) in the medium.
2.3. Single-channel recordings
Single-channel currents were recorded in the cell-attached
conﬁguration [21] at a membrane potential of −80 mV and 20 °C
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Inc., CA), digitized at 94 kHz with an ITC-16 interface (Instrutech
Corporation, Long Island, NY) and transferred to a computer using the
program Acquire (Bruxton Corporation, Seattle, WA). The bath and
pipette solutions contained 142 mM KCl, 5.4 mM NaCl, 1.8 mM CaCl2,
1.7 mMMgCl2 and 10 mM HEPES (pH 7.4). Patch pipettes were pulled
from Kimax-51 capillary tubes (Kimble Products, Vineland, NJ), coated
with Coat D (M-Line accessories, Measurements Group, Raleigh, NC),
and ﬁre-polished. Pipette resistances ranged from 5 to 7 MΩ. LTG was
prepared from a 10 mM stock solution in ethanol, stored at −20 °C.
ACh working solutions (30 μM) were dissolved in the bath solution
from a 10 mM stock solution which was normally kept stored at
−20 °C. Following ethanol evaporation under a stream of N2, LTG was
dissolved in the bath solution (0.05–400 μM) and then applied to the
channel from the pipette tip. Detection of single-channel events using
the program TAC followed the half-amplitude threshold criterion
(Bruxton Corporation, Seattle WA) at a bandwidth of 5 kHz. The
sampling time was 20 μs and the minimum detectable interval was
0.066 ms [22]. Open, burst and closed-time histograms were plotted
using a logarithmic abscissa and a square root ordinate and ﬁtted to
the sum of exponential functions by themaximum likelihood criterion
using the program TACFit (Bruxton Corporation, Seattle, WA). Burst
resolution was obtained from the intersection between the main
closed-time component and the succeeding one.
2.4. Whole-cell recordings
The extracellular solution contained 140 mM NaCl, 5 mM KCl,
1.8 mM CaCl2, 1.7 mM MgCl2 and 25 mM HEPES, pH 7.4, and the
intracellular solution contained 145 mM KCl, 5 mM NaCl, 1 mM EGTA
and 25 mM HEPES, pH 7.4. Pipette resistances ranged from 3 to 4 MΩ.
Upon high-resistance sealing, cells were lifted from the bottom of the
dish and ACh, LTG or extracellular solution was delivered using aFig. 1. LTG exerts agonist (at low concentration) and inhibitory (at high concentration) effect
closed (right) time histograms of single-channel recordings obtained in the cell-attached con
Filter: 5 kHz.Warner SF 77 Fast Step perfusion system (Warner instruments,
Hamden, CT) under computer control. Using this setup, the solution
around the cell could be completely exchanged within 10–15 ms.
Whole-cell currents were recorded at different holding potentials at
20 °C using an Axopatch 200B and transferred to a computer using the
program PULSE (HEKA GmbH, Lambrecht, Germany). The cells were
exposed to the agonist ﬂow for 2 s andwashedwithmedium to enable
multiple recordings while avoiding signiﬁcant desensitization. Cur-
rents were measured every 2–3 min. LTG and ACh were applied to
different cell dishes.
2.5. Fluorescence microscopy
CHO-K1/A5 cells were grown on 25 mm diameter glass coverslips
in Ham's-F 12 medium for 2–3 days at 37 °C. Cells were washed twice
withM1 buffer (150mMNaCl,1mMCaCl2,1mMMgCl2, and 5mMKCl
in 20 mM HEPES buffer, pH 7.4) and stained for 1 h on ice with Alexa
Fluor488-αBTX at a ﬁnal concentration of 1 μM. Cells were then rinsed
three times with M1, mounted, and imaged using a wide-ﬁeld Nikon
Eclipse E-600 microscope using a 60× (1.4 N.A.) or 40× (1.0 N.A.)
objective and digitized with a model ST-7 SBIG digital charge-
coupled device camera (765×510 pixel, 9.0×9.0 mm pixel size; Santa
Barbara, CA), thermostatically cooled at −10 °C. The ST-7 CCD camera
was driven by the CCDOPS software package (SBIG Astronomical
Instruments, version 5.02). Appropriate dichroic and emission ﬁlters
were employed to avoid crossover of ﬂuorescence emission. Back-
ground images were acquired from areas without cells from the
same specimen and 16-bit TIFF images were exported for further off-
line analysis. Fluorescence images were analyzed with the software
Scion Image version 4.0.2 (Scion Corporation, Frederic, MD). The
average ﬂuorescence intensity over distinct areas of the cell surface
was calculated for cells chosen at random for each experimental
condition.s on muscle AChR. (A) Raw single-channel traces and (B) open (left), bursts (centre) and
ﬁguration from CHO-K1/A5 cells expressing adult AChR. Membrane potential: −80 mV.
Fig. 1 (continued).
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LTG binding to the AChR was determined using a [125I]αBTX
binding assay. CHO-K1/A5 cells were re-suspended in high potas-
sium Ringer's solution. Cells were pre-incubated for 30 min in the
absence or presence of LTG (10−4–103 μM) or αBTX (10−4–10 μM) or
Carb (10−2–106 μM) and [125I]αBTX was added to a ﬁnal concentra-
tion of 20 nM for an additional 60 min. Binding was stopped by
centrifugation for 5 min at 2000×g. Each experiment was carried out
twice in triplicate and results were analyzed by normalizing to the
binding in the absence of any competitive ligand. Radioactivity was
measured in a gamma counter with an efﬁciency of 80%.
2.7. Fluorescence assay of AChR conformational states
Membrane fragments rich in AChR were prepared from the
electric tissue of T. californica as previously described [23]. Speciﬁc
activities in the order of 2.0–2.8 nmol αBTX sites/mg protein were
obtained. The orientation of AChR in the membrane vesicles was
determined by comparing the total toxin-binding sites in the
presence of Triton X-100 and the right-side-out toxin-binding sites
in the absence of detergent [24–25]. For the ﬂuorescence measure-
ments, AChR-rich membranes were suspended in buffer A (150 mM
NaCl, 0.25 mM MgCl2, and 20 mM HEPES buffer, pH 7.4) at a ﬁnal
concentration of 100 μg protein/mL (0.4 μM in terms of toxin-
binding sites).Fluorescence measurements were performed in an SLM model
4800 ﬂuorimeter (SLM Instruments, Urbana, IL) using a vertically
polarized light beam from a Hannovia 200-W mercury/xenon arc
obtained with a Glan-Thompson polarizer (4-nm excitation and
emission slits) and 2 mL quartz cuvettes. The temperature was set at
25 °C with a thermostated circulating water bath (Haake, Darmstadt,
Germany). Increasing quantities of CrV were added to the samples
from an aqueous solution; after each addition the emission spectra
were collected (excitation wavelength: 600 nm; scanning from 605 to
700 nm). From the emission spectrum collected in the presence of CrV,
a spectrum obtained from the same cuvette before CrV addition
(background) was subtracted and the maximum intensity (at 624 nm)
was measured. For experiments carried out on desensitized AChR,
1 mM Carb was added 15 min before titration with CrV.
2.8. Data analysis
Data are expressed as mean±S.D. from independent experiments.
Statistical analysis was performed using Student's t test.
3. Results
3.1. LTG activates the muscle-type AChR
Single-channel studies were performed on CHO-K1/A5 cells to
evaluate the effect of the anticonvulsive drug LTG on AChR channel
Table 1
Single-channel kinetic parameters of Lamotrigine at membrane potential − 80 mV
LTG [μM] τopen (ms) Amplitude (pA) τclose1 (ms) τclose1 relative weight τblocked (ms) τ blocked relative weight
0.05 (n=3) 0.90±0.08 6.36±0.07 0.38±0.28 0.04±0.02 – –
0.10 (n=5) 0.92±0.13 6.75±0.38 0.11±0.05 0.03±0.01 – –
0.25 (n=3) 0.96±0.07 5.82±0.01 0.27±0.01 0.06±0.00 – –
1.00 (n=6) 0.92±0.08 6.00±0.35 0.33±0.11 0.08±0.03 – –
2.50 (n=4) 0.87±0.08 6.18±0.28 0.27±0.04 0.04±0.01 – –
5.00 (n=3) 0.77±0.14 5.86±0.34 0.20±0.04 0.08±0.02 – –
20.0 (n=4) 0.71±0.11⁎ 6.12±0.13 0.20±0.06 0.13±0.03⁎⁎ – –
50.0 (n=5) 0.63±0.09⁎⁎ 6.44±0.09 0.20±0.05 0.44±0.17⁎⁎ 1.60±0.66 0.08±0.02
100 (n=6) 0.40±0.06⁎⁎ 6.09±0.47 0.19±0.05 0.28±0.12⁎⁎ 1.67±0.81 0.08±0.05
200 (n=3) 0.29±0.06⁎⁎ 4.85±0.38 0.19±0.08 0.35±0.18⁎ 1.58±0.64 0.13±0.03
400 (n=3) 0.26±0.05⁎⁎ 4.98±0.44 0.22±0.09 0.37±0.17⁎ 1.24±0.58 0.08±0.06
⁎ Statistically signiﬁcant differences with respect to 0.05 µM LTG (pb0.05).
⁎⁎ Statistically signiﬁcant differences with respect to 0.05 µM LTG (pb0.01).
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were exposed to LTG in the concentration range 0.05 to 400 μM. Fig.1A
shows raw traces of currents elicited by LTG. LTGwas found to activate
the AChR at all concentrations tested, opening the AChR channel at
sparse intervals (see Supplementary data). As shown in Table 1, at the
lowest concentration range assayed (0.05–20 μM) the kinetic para-
meters of the LTG-activated channels proved to be similar to those
observed in previous studies at low concentrations of the natural
agonist ACh [18–26]. The distribution of single-channel openings
ﬁttedwell to a single exponential function (Fig. 1B and Supplementary
data). Two components contributed to τburst in most recordings at LTG
concentrations above 2.5 μM. The longest component (∼2 ms)
probably reﬂects the occurrence of opening events in bursts in the
presence of LTG, whereas the shortest in duration but of higher
relative weight (relative amplitude b0.67) corresponds to individual
openings (Fig. 1B and Supplementary data). Two main closed-time
components were observed in the recordings (Fig. 1B and Supple-
mentary data). The briefer, τclosed1, component is always present in
AChR closed-time duration histograms and most likely corresponds to
the reopening of the closed channel before it ﬁnally reaches either a
desensitized or an unliganded state. The longest, τclosed2, is related to
the number of channels in the patch [27].
We further analyzed the AChR channel behavior at higher LTG
concentrations (50–400 μM). At these concentrations, in addition toFig. 2. Mean number of openings per bursts as a function of LTG concentration. Each
point corresponds to the average±SD of at least three independent experiments.
Statistically signiﬁcant differences with respect to control values were indicated as
follows: *pb0.01; **pb 0.007.causing the channel to open, LTG also caused a concomitant reduction
in τopen (Fig. 1, Table 1 and Supplementary data) that is likely
attributable to channel block (see below). The presence of two
components contributing to τburst was evident at these concentra-
tions. The duration of the longest τburst was similar to that observed
for low LTG concentrations. Interestingly, as the LTG concentration
increased, a reduction in the duration of the shortest τburst component
was observed (Fig. 1B). Increasing the drug concentration caused a
concomitant increase in the number of openings per burst from 1.61±
0.15 (n=3) at 0.05 μM to 6.43±1.44 (n=3) at 400 μM LTG. Even though
this change was statistically signiﬁcant (Fig. 2), the extent of the effect
caused by LTG was not as strong as that exerted by the natural agonist
ACh (Fig. 2 and see Fig. 4B).
Analysis of the closed-time distributions obtained at high LTG
concentrations provided additional diagnostic criteria. The relative
weight of the briefer closed-time component was signiﬁcantly higher
than that obtained at lower LTG concentrations (Figs. 1 and 3, Table 1
and Supplementary data). This increase could be related to the
grouping of AChR apertures induced by LTG, as visualized in the raw
traces. A new minor component of ∼1.50 ms was also observed (see
Table 1). We interpret this new component as the result of the channel
blocking events, and hence refer to it hereafter as τblocked. The fact
that the duration of the blocked state did not increase with LTG
concentration suggests that the blocking mechanism involves single-
liganded LTG, as observedwith galantamine blockage of the AChR [11].Fig. 3. Dependence of mean open time (τopen) on LTG concentration. Values were
extracted from the dwell-time histograms of single-channel data in the presence of LTG.
Inset: reciprocal of τopen vs. LTG concentration.
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0.05–400 μM concentration range (Table 1). At 200 and 400 μM, an
additional closed-time component was apparent (Fig. 1B and
Supplementary data). This component can be attributed to the
desensitization, as commonly observed with other agonists at high
concentrations [28].
3.2. LTG activates and blocks the muscle-type AChR
The blocking effect of LTG on AChR channels activated by the
natural agonist AChR was accounted for in terms of a linear blocking
mechanism [29–32] in a recent paper from our laboratory [18]. Here,
the kinetics of channel blockage when AChR channels are activated
with LTG (Fig. 3) are analyzed in terms of the classical sequential
blocking scheme:
where C, O and OB represent the closed, open and open-blocked states
of the AChR, respectively; α and β are the apparent closing and
opening rate constants, respectively; f[B] and b are the apparent
forward and backward rate constant for the blocking effect. The
constants f[B], α and bwere calculated to be 7.89×106 M−1 s−1, 1219 s−1
and 611 s−1, respectively. The resulting apparent dissociation constant
for the blocking process, Kd, was 77.4 μM. No signiﬁcant differences
were apparent between these values and those found in the
simultaneous presence of ACh and LTG [18].
3.3. LTG can activate whole-cell currents in muscle-type AChR
We asked next whether LTG could induce whole-cell currents in
CHO-K1/A5 cells. We ﬁrst obtained inwardly rectifying agonist-
elicited currents after applying a 2 s pulse of 50 μM ACh at different
membrane potentials (−80, −70 and −50 mV) to CHO-K1/A5 cells
(Fig. 4A). Fig. 4A shows the induction of macroscopic whole-cell
inward current responses after an application of a 2 s pulse of 100 μM
LTG to another group of CHO-K1/A5 cells.
3.4. Effects of LTG on ACh-activated AChR channels
Given the dual action of LTG–AChR channel activator and inhibitor
[18], we next focused on the characterization of ACh openings in the
presence of LTG. For this purpose AChR channels were activated by
ACh at a concentration that causes the channel to open in bursts.Fig. 4. LTG-generated currents. Whole-cell currents were recorded after application of a 2 s p
100 μM LTG at −110, −90, −80 and −70 mV.Wild-type AChRs open in well-deﬁned activation episodes and
subsequently desensitize at ACh concentrations above ∼10 μM
[33–34]. An activation episode starts with the transition of a single
receptor from the desensitized to the activatable state and ﬁnishes
upon returning to the desensitized state [33–34]. Using a pipette ACh
concentration of 30 μM (Fig. 5A) AChR channels behaved as
previously reported [26]. Channel opening distribution consisted of
single openings that lasted ∼1 ms. Three closed-time components
were observed. The main component (relative weight 0.91±0.08)
was fast, with an average duration of 0.60±0.11 ms. Two τburst
components of equal contribution were observed, τburst1 and τburst2,
lasting 0.38±0.13 ms and 63±25 ms, respectively (Fig. 5B). The latter
corresponds to the duration of a cluster.
We then co-applied 1 μM LTG with 30 μM ACh and channel kinetics
were compared with those of 30 μM ACh alone. This LTG concentration
was chosen because it activates the channel (Fig. 1B) but does not
inhibit it in the presence of low ACh concentrations, as previously
reported [18]. Under these conditions, τopen was undistinguishable
from that observed with ACh alone. However, although three closed-
time components were also observed, their relative contribution varied
notably (Fig. 5B). The most relevant ﬁnding became apparent with the
τburst analysis. Firstly, although the duration of τburst1 and τburst2
remained unaltered, their relative contribution changed considerably.
Thus the relative weight of τburst1 increased with a concomitant
decrease in τburst2. Secondly, a new component with a 1.97±0.58 ms
duration, τburst3, was observed. This latter component can be attributed
to the LTG-mediated induction of openings in groups.
As shown in Fig. 5C, the τburst histogram obtained using co-
application of 30 μMACh plus 1 μM LTG could be qualitatively ﬁtted to
the sum of the histograms obtained for the independent application of
each drug, albeit changing the distribution but not the duration of
τburst. The most plausible interpretation of this ﬁnding is that the
equilibrium that allows the channel to open, close, reopen and ﬁnally
close by desensitization, changes in the presence of LTG, shifting
towards the shortest τburst component. Conversely, ACh did not affect
the action of LTG, as reﬂected by the fact that the τburst component
elicited by LTG alone could be distinguished from the τburst histogram
obtained under co-application conditions. Clusters of openings were
not observed when AChR channels were activated by LTG alone at any
of the concentrations tested (Fig. 1A) as evidenced by the lack of any
effect on the longest ACh-activated τburst component. This ﬁnding
suggests that co-application of the full agonist together with LTG
results in channel activation but does not promote cluster formation.
To further test this hypothesis, another series of experiments was
performed increasing the LTG concentration to 50 μM and again co-
applying the drug with 30 μM ACh (Fig. 5B). This resulted in a slightulse of (A) 50 μM ACh at different membrane potentials (−80, −70 and −50 mV) and (B)
Fig. 5. LTGmodiﬁes AChR channel gating kinetics. Raw traces of single-channel recordings obtained in the cell-attached conﬁguration from CHO-K1/A5 cells expressing adult AChR in
the presence of (A) 30 μM ACh (upper row); 30 μMACh+1 μM LTG (middle row) and 30 μMACh+50 μM LTG (bottom row). (B) Open (ﬁrst column), closed (second column) and burst
(third column) time histograms resulting from the analysis of the recordings. (C) Comparison between burst time histograms resulting from the analysis of: (a) 30 μM ACh, (b)1 μM
LTG, (c) 30 μM ACh+1 μM LTG, and (d) 30 μM ACh+50 μM LTG recordings. Membrane potential: −80 mV. Filter: 5 kHz.
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component of τclosed of ∼2 ms became apparent. We infer that this
new closed-time component most likely corresponds to τblocked, as
previously observed with LTG (50 to 400 μM). The main change
observed was the relative increase in τburst3, thus reinforcing the
above conclusion (Fig. 5C).
3.5. LTG induces the transition from the resting to the desensitized state
of the Torpedo AChR
Having observed that LTG alone activates AChR channels, we
studied next whether the presence of LTG induces the same type of
conformational changes as classical agonists. Towards this end,
ﬂuorescence spectroscopy experiments were carried out using
AChR-rich Torpedo californica membranes (in which more than 50%
of the protein content corresponds to AChR protein) and the probe
CrV. The latter is an aminotriarylmethane ﬂuorescent dye that
behaves as an AChR ion blocker and displays higher afﬁnity for the
AChR desensitized conformation (D) than for the AChR resting
conformation (R) [35]. We took advantage of these differences in
afﬁnity to monitor changes in AChR conformational states in thepresence of LTG (2.5–500 μM). CrV was directly titrated into a
suspension of Torpedo AChR-rich membranes, and the apparent KDs
were obtained by ﬁtting the experimental values of CrV ﬂuorescence
to CrV concentration with a sigmoid equation (Fig. 6A). The control
KDs of CrV in the R (without Carb) and D (with 1 mM Carb) states were
326.4±31 and 43.8±10 nM, respectively. When LTG was added to the
membranes instead of Carb, the KD of CrV decreased in a concentra-
tion-dependent manner with respect to the control value of the R
state (Fig. 6B), and saturated at low LTG concentrations. The KD of CrV
calculated for membranes treated ﬁrst with Carb and then with
different concentrations of LTG was similar to that obtained with
membranes treated with Carb alone. This series of experiments
indicates that LTG effectively induces a state transition of the receptor,
compatible with the behavior of an AChR agonist. Once this transition
occurs, further addition of LTG causes no additional changes.
In order to dissect the dual behaviour of LTG, similar studies were
performed with membranes previously incubated with the competi-
tive antagonist αBTX at a concentration that effectively blocks the
agonist binding site. The apparent KD of CrV was similar to that
observed for the R state in the presence of αBTX (Fig. 6B, inset). When
the full agonist Carb was added after incubation of the membrane
Fig. 6. (A) Speciﬁc ﬂuorescence of CrV in the absence (■) or presence (□) of 1 mM Carb. CrV was directly titrated into a suspension of AChR-rich membranes from Torpedo. The
apparent KD's (see Results section) were obtained by ﬁtting the experimental values of CrV ﬂuorescence versus CrV concentration with a sigmoid equation (data from at least four
separate experiments). (B) Variations in the KD-ratio of the experimentally determined KD values to the control KD obtained in the resting state in the presence of increasing
concentrations of LTG. The values were obtained with AChR-rich membrane alone (■), or in the presence of 1 mM Carb (□) or 1.5 μM αBTX (●). Inset: KD-ratio calculated in the
presence of 1 mM Carb, 1.5 μM αBTX or 1 mM Carb plus 1.5 μM αBTX. (C) Comparison between LTG and the ion channel blocker QX-314. The values were obtained with AChR-rich
membranes alone (black columns), or in the presence of 1 mM Carb (white columns), or 1.5 μM αBTX (grey columns). (D) KD-ratio calculated in the presence of physostigmine (5 and
100 μM), galantamine (5 and 100 μM) and LTG (5 and 100 μM) alone (black columns), or in the presence of 1 mM Carb (white columns) or 1.5 μM αBTX (grey columns). Each column/
symbol corresponds to the average±S.D. of at least four independent experiments.
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binding sites were completely blocked (Fig. 6B, inset); however, when
LTG was added subsequent to αBTX incubation the KD of CrV
decreased in a manner similar to that observed with LTG alone,
indicating that LTG can activate the AChR even though the agonist
binding sites are blocked (Fig. 6B). This result further suggests that the
modulatory effect of LTG is exerted on different sites.
At high concentrations, LTG also behaves as an ion channel
blocker, as is the case with CrV. One would thus expect that LTG
competes with the ﬂuorescence dye, displacing it from the ion pore,
hence leading to an increase in KD. However, this was not the case
even at LTG concentrations as high as 500 μM, or using both αBTX
and LTG (Fig. 6B). The canonical AChR channel blocker QX-314 was
tested next for comparison (Fig. 6C). The KD of CrV obtained in
membranes treated with QX-314 alone, or after incubation with
αBTX or Carb, was similar to that of the R state. The differences
between the CrV-sensitive AChR states in the presence of 500 μM LTG
or QX-314 conﬁrm the observation that LTG has a dual effect on the
AChR: at high concentrations, LTG not only acts as an ion channel
blocker but also activates the AChR, the latter effect possibly beingresponsible for the AChR state transitions revealed here by CrV
ﬂuorescence spectroscopy experiments.
We studied next the effect of galantamine and physostigmine, two
APL of the AChR, on the conformational equilibrium of the Torpedo
AChR (Fig. 6D). Neither galantamine nor physostigmine alone induced
changes in the KD of CrV with respect to the control value for the R
state. Furthermore, when these APL were added after incubation of
the membranes with αBTX or Carb, the KD of CrV did not change with
respect to the controls, suggesting that LTG modulates the AChR
through a mechanism different from that operating with APL.
3.6. LTG effects on the binding of αBTX to living CHO-K1/A5 cells
To corroborate that LTG binds to a different site from the ACh-
binding site, two additional series of experiments were performed.
First, the initial rate of [125I]αBTX binding [36] was measured in CHO-
K1/A5 cells after 30min pre-incubationwith LTG (10−4–103 μM). In the
concentration range assayed, LTG did not affect [125I]αBTX binding to
the AChR (Fig. 7A). Similar experiments were performed after pre-
incubation of cells with the full agonist Carb or the antagonist αBTX
Fig. 7. (A) Initial rate of [125I]αBTX binding to AChR in CHO-K1/A5 cells is not affected by
LTG. (B) Reduction of the initial rate of [125I]αBTX binding by the full agonist Carb
(triangles), the competitive antagonist αBTX (circles), and Carb plus 100 μM LTG
(squares).
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IC50 for inhibition by Carb and αBTX were 35 μM and 36 nM,
respectively (Fig. 7B). When LTG (100 μM) was applied together with
different concentrations of Carb (Fig. 7B) the inhibition curve for Carb
shifted to lower IC50 values (∼2.6 μM) indicating that in the presence
of LTG, Carb exhibits a higher afﬁnity for the AChR.
To further conﬁrm the lack of inhibition of [125I]αBTX binding by
LTG alone, Alexa Fluor488αBTX staining of live CHO-K1/A5 cells was
carried out (Fig. 8). 2 h incubation with 100 μM Carb signiﬁcantly
reduced cell-surface ﬂuorescence (Fig. 8A, B), whereas the ﬂuores-
cence intensity of cells incubated with concentrations as low as 50 μM
LTG (Fig. 8C, D) or as high as 300 μM LTG under periods of up to 24 h,
did not differ from that of control samples (Fig. 8E, F). These results
indicate that LTG does not compete with the canonical competitive
antagonist αBTX, in agreement with the ﬂuorescence spectroscopy
experiments (Fig. 6).
4. Discussion
A wide range of compounds has the ability to modulate the AChR.
This modulation can be accomplished through different mechanisms,
involving the agonist site, the pore itself, or amino acid residues in the
transmembrane moiety of the AChR, the former and the latter
mechanisms usually resulting in allosteric regulation [1,37]. ACh
binds to the AChR at a well-deﬁned pocket lined up with aromatic
residues located at an interface between the α and non-α subunits.In this work the effect of the anticonvulsive drug LTG on muscle
AChRs was studied using a combination of single-channel and whole-
cell patch-clamp recordings, ﬂuorescence spectroscopy, ﬂuorescence
microscopy and radioligand binding strategies. The most notable
ﬁnding of this work is that LTG, by itself, activates the muscle-type
AChR at all concentrations tested, as evidenced by single-channel and
whole-cell recordings (Figs. 1 and 4). Activation of the AChR by LTG
exhibited several similarities with the action of the natural agonist,
ACh. In agreement with the electrophysiological data, ﬂuorescence
spectroscopy experiments showed that upon binding to the AChR, LTG
induces a transition from the resting (closed) state to the desensitized
state. Altogether, these observations are compatible with an agonist
effect of LTG.
At high LTG concentrations (50–400 μM) a blocking effect became
evident, as previously observed in the case of ACh activation [18]. LTG
caused (a) a decrease in channel mean open time (Fig. 1 and
Supplementary data), (b) an increase in the mean burst duration
(Fig. 1 and Supplementary data), (c) an increase in the number of
openings per burst (Fig. 2) and (d) the appearance of a new closed
channel component (“blocked time”, Fig. 1). The duration of the latter
remained constant at the concentrations tested (50–400 μM) whereas
its relative weight showed a concentration-dependent behavior. In
contrast to previous reports on the action of the open-channel
blocking effect of tacrine on muscle-type AChR [38], a single LTG
molecule appears to be involved since the duration of the closed state
did not increase with LTG concentration. At the higher LTG
concentrations tested (200 and 400 μM), desensitization became
apparent with the appearance of a new closed-time component in the
range of seconds (Fig. 1 and Supplementary data).
The simple channel-block model was used to describe the LTG
blockage of LTG-activated channels. Inclusion of a desensitization
pathway in this mechanistic description is not applicable because
AChRmean open time diminishes as LTG concentration increases [18],
and the high agonist concentrations required to obtain well-deﬁned
clusters of channel openings would result in complete channel
blockage by LTG. The blocking action of LTG could be satisfactorily
explained with this model in which the rapid dissociation of the drug
shortens the channel open state and delays AChR closure, thus
preventing transitions to the closed state leading to lengthier burst
duration. No differences were found between the present analysis and
the one satisfactorily describing the combined action of ACh and LTG
[18] suggesting that the blocking potency of LTG is not inﬂuenced by
the AChR-activating drug and that LTG activation and blocking are
independent.
LTG was additionally found to modify τclose and τbursts distribution
of the AChR channel. Electrophysiological recordings obtained after
application of ACh (30 μM) to the AChR showed that the channel
opened preferentially in clusters and seldomly in the form of isolated
openings, in contrast to what is observed at low ACh concentrations
(1 μM). When LTG was co-applied with ACh a reduction in the relative
weight of the fastest closed-time component was observed. This
component is likely to correspond to the time spent by the channel in
the closed state within a cluster. A concomitant increase in the
amplitude of the faster of the two slow components, which
corresponds to the duration of the channel in the closed state in
between isolated openings, was also observed (Fig. 5). We interpret
this phenomenon as resulting from LTG induced openings of the AChR.
Furthermore, concentrations of LTG that cause blockage of the channel
(50 μM) resulted in the appearance of τblocked.
Piecing together the experimental evidence leads to the conclusion
that LTG acts on sites different from those of nicotinic agonists,
competitive antagonists or APL-type molecules, e.g. galantamine or
physostigmine. LTG mimicked the response observed with a typical
agonist (Carb) in ﬂuorescence experiments even under conditions of
αBTX blockage of the agonist binding sites, suggesting that the
modulation of LTG occurs through a different site. LTG has two
Fig. 8. Cell-surfaceαBTX ﬂuorescence binding is not affected by LTG. CHO-K1/A5 cells were cultured in serum-freemedium for 2 h in the absence (A and C) or presence of 100 μMCarb
(B) or 50 μM LTG (D), or 24 h in the absence (E) or presence (F) of 300 μM LTG. Surface AChRs were stained with the ﬂuorescent probe Alexa Fluor488-αBTX. The bar indicates 10 μm.
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be responsible for the agonist effect; however, this possibility can be
discarded because LTG at pH 7.4 is in its non-ionized form [39].
QX-314, a well known open-channel blocker of the AChR, did not
modify the KD of CrV in Torpedo californica AChR-rich membranes by
itself or in the presence of αBTX or Carb, suggesting that the
transitions made apparent by CrV ﬂuorescence changes are the result
of LTG acting as an activator rather than as a channel blocker. These
results are fully compatible with the inability of LTG to inhibit the
initial rate of [125I]αBTX binding (Fig. 7). Similarly, ﬂuorescence
microscopy studies showed that Alexa488αBTX cell-surface staining
was not affected by LTG (Fig. 8). Collectively, the results support the
hypothesis that LTG binds to a site different from the canonical
agonist- and competitive antagonist-recognition site.
We further compared the effects of the most common APL-type
molecules, galantamine and physostigmine, with those of LTG. Both
drugs have previously been reported to activate the muscle AChR
[11,12]. Activation apparently proceeds through sites distinct from
those for nicotinic agonists and antagonists. No similarities were
observed between the desensitizing properties of LTG and those of
galantamine or physostigmine (Fig. 6D). A marked difference between
LTG on the one hand and galantamine and physostigmine on the other
is the fact that LTG elicited whole-cell currents by itself whereas the
latter drugs do not [40–41]. Additionally, marked differences existbetween the solubility properties of the two APL (water soluble) and
LTG (soluble in organic solvents), further reinforcing the idea that LTG
probably binds to a site different from that of the APL and has a
different degree of hydrophobicity.
Finally, the results presented in Fig. 7 provide additional evidence
that LTG alone can desensitize the AChR. Radioligand binding
experiments demonstrated that when LTG was applied together
with increasing concentrations of Carb, the IC50 for inhibition by Carb
was reduced from ∼35 μM to ∼2.6 μM, indicating that in the presence
of LTG, Carb exhibits higher afﬁnity for the AChR [36,42].
In conclusion, the drug LTG makes apparent a new mode of AChR
activation, which differs from that of the classical agonists and APL.
Although AChRs are not the speciﬁc targets for the anticonvulsive
action of LTG, experiments are now in progress to investigate whether
some of the collateral effects of LTG in the central nervous system can
be accounted for by the effect of this drug on neuronal AChRs.
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